It is also approved for?AIDS-related Kaposi sarcoma?after failure of highly active antiretroviral therapy, as well as for HIV-negative adult patients with Kaposi sarcoma
Built on the Percept Platform and enhanced with BrainSense technology, the system can adjust stimulation levels in real time, responding to brain signals without manual intervention
SYNT-101 is a once-daily oral pill engineered to redirect nutrient absorption beyond the small intestine’s duodenum
The product addresses a market with approximately $66.8 million in annual sales as of December 2025.
The TacroType test provides actionable genetic insights to help clinicians understand how individual patients metabolize tacrolimus
Zydus has developed an innovative Semaglutide Injection (15 mg/3 ml) in a prefilled cartridge administered using a patient-friendly reusable pen for which the company has exclusive rights
The innovative eyedrop targets inflammation and pain following ocular surgery
Brivaracetam is the bioequivalent to Briviact Oral Solution, 10 mg/mL, of UCB
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
The move follows encouraging Phase I data and a series of regulatory wins from the U.S. Food and Drug Administration
Subscribe To Our Newsletter & Stay Updated
